Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Quinine Sulfate

FDA-approved product (capsule, oral), marketed as Qualaquin, Quinine Sulfate.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Quinine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria
  • Muscle cramp
  • Plasmodium falciparum malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Quinine and derivatives; Methanolquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BC01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Quinine Sulfate in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Quinine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

    NCT00727272 · start 2004-02

    Registered record
    Registry ID
    NCT00727272
    Conditions
    Healthy
    Interventions
    Quinine Sulfate Capsules 324 mg; Quinine Sulphate Tablets 300 mg; Quinine Sulfate Capsules 324 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-03
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionQuinine Sulfate Capsules 324 mg; Quinine Sulphate Tablets 300 mg; Quinine Sulfate Capsules 324 mg
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine

    NCT00167739 · start 2003-04

    Registered record
    Registry ID
    NCT00167739
    Conditions
    Malaria
    Interventions
    Quinine plus sulfadoxine-pyrimethamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2004-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionQuinine plus sulfadoxine-pyrimethamine
    PhasePhase 4
    Registry statusCompleted

  • Cotrifazid Safety and Efficacy Against Malaria

    NCT00322907 · start 2000-04

    Registered record
    Registry ID
    NCT00322907
    Conditions
    Clinical Malaria
    Interventions
    Cotrifazid vs mefloquine or quinine+SP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2000-04
    Completion
    2003-01
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Malaria
    InterventionCotrifazid vs mefloquine or quinine+SP
    PhasePhase 2
    Registry statusTerminated

  • Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine

    NCT00000706

    Registered record
    Registry ID
    NCT00000706
    Conditions
    HIV Infections
    Interventions
    Quinine sulfate; Probenecid; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1988-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionQuinine sulfate; Probenecid; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

    NCT00451139

    Registered record
    Registry ID
    NCT00451139
    Conditions
    Malaria
    Interventions
    artemether/lumefantrine; quinine; atovaquone/proguanil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionartemether/lumefantrine; quinine; atovaquone/proguanil
    PhasePhase 4
    Registry statusCompleted